Request a Rep & More Information About KENGREAL® (cangrelor)
To be contacted by a sales representative or to receive updates when new information becomes available, please fill out the form below and provide us with your preferred contact information.
Medical Information
To request specific medical information about KENGREAL or to report adverse events or product complaints, contact the Medical Information Department.
Adverse events may also be reported to the FDA’s MedWatch Program at 1-800-FDA-1088.
Mail:
Chiesi USA, Inc.
175 Regency Woods Place
Suite 600
Cary, NC 27518
Important Safety Information
KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.
KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.
Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.
The most common adverse reaction is bleeding.
Please see Full Prescribing Information.
Indication
KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.